keyword
MENU ▼
Read by QxMD icon Read
search

Small cell lung cancer

keyword
https://www.readbyqxmd.com/read/29792183/estimated-intraoperative-blood-loss-correlates-with-postoperative-cardiopulmonary-complications-and-length-of-stay-in-patients-undergoing-video-assisted-thoracoscopic-lung-cancer-lobectomy-a-retrospective-cohort-study
#1
Shuangjiang Li, Kun Zhou, Yutian Lai, Cheng Shen, Yanming Wu, Guowei Che
BACKGROUND: The purpose of our study was to estimate the influence of estimated intraoperative blood loss (EIBL) on postoperative cardiopulmonary complications (PCCs) in patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy for non-small-cell lung cancer (NSCLC). METHODS: We conducted a single-center retrospective analysis on the clinical data of consecutive patients in our institution between April 2015 and February 2016. Demographic differences between PCC group and non-PCC group were initially assessed...
May 23, 2018: BMC Surgery
https://www.readbyqxmd.com/read/29791936/is-right-sleeve-lower-lobectomy-necessary-is-it-safe
#2
Celalettin Ibrahim Kocaturk, Ozkan Saydam, Celal Bugra Sezen, Cem Emrah Kalafat, Levent Cansever, Ali Cevat Kutluk, Hasan Akin, Muzaffer Metin
OBJECTIVES:  The right sleeve lower lobectomy is the least used of the bronchial sleeve operations. There are only case-based studies in the literature. In this study, we compared this technique to those used in patients who underwent a right lower bilobectomy. METHODS:  We retrospectively reviewed the data of patients who had been operated on due to non-small cell lung cancer (NSCLC) from January 2005 to December 2015 from a dataset that was formed prospectively...
May 23, 2018: Thoracic and Cardiovascular Surgeon
https://www.readbyqxmd.com/read/29791705/is-there-a-role-for-vats-sleeve-lobectomy-in-lung-cancer
#3
Natalie N Merchant, Robert McKenna, Osita Onugha
Lung cancer is the second most commonly diagnosed cancer and continues to be the leading cause of death for both men and women, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancer cases. Once a lung mass is visualized on imaging, accurate staging is required for determination of treatment options and, when possible, surgical resection is recommended as it has been proven to have the best survival rates versus non-surgical treatment. If a patient has advanced or metastatic disease, therapeutic options include chemotherapy and radiation, while immunotherapy and specific agents that target tumor mutations are only recommended for appropriate candidates...
June 1, 2018: Surgical Technology International
https://www.readbyqxmd.com/read/29791232/the-role-of-interleukin-31-polymorphisms-in-non-small-cell-lung-cancer-genetic-susceptibility-and-clinical-outcome
#4
Yongfeng Yang, Li Li, Fei Chen, Li Zhang, Hong Bu
BACKGROUND: Interleukin-31 (IL-31), a novel T helper type 2 effector cytokine, is known to have an important effect on the pathogenesis of allergic disease and tumors. However, the impact of IL-31 on human lung cancer remains unclear. METHODS: This study explored the role of IL-31 polymorphisms in lung cancer and sought to characterize how IL-31 polymorphisms correlate with lung cancer tumorigenesis and patient survival rates. Using a single-nucleotide polymorphism genotype assay, we examined the expression of two IL-31 polymorphisms (rs7977932 and rs4758680) in samples from 302 lung cancer patients and 493 control cases...
May 2018: Genetic Testing and Molecular Biomarkers
https://www.readbyqxmd.com/read/29790995/late-radiological-changes-after-passive-scattering-proton-beam-therapy-for-stage-i-lung-cancer
#5
Naoki Nakamura, Hidehiro Hojo, Kazuya Inoue, Kenji Hotta, Sadamoto Zenda, Hiromi Baba, Masakatsu Onozawa, Atsushi Motegi, Masaki Nakamura, Yuichi Kibe, Tetsuo Akimoto
This study aimed to examine late radiological changes after proton beam therapy (PBT) for early-stage non-small cell lung cancer (NSCLC) and to clarify correlations between mass-like radiological changes and patient characteristics. CT scans of patients who underwent passive scattering PBT for T1-2N0M0 NSCLC were analyzed retrospectively. Patients were considered eligible if follow-up CT was performed for at least 2 years, with no definite evidence of local recurrence. The following five periods were defined: (i) 6-12 months, (ii) 12-24 months, (iii) 24-36 months, (iv) 36-48 months and (v) 48-60 months after PBT...
May 21, 2018: Journal of Radiation Research
https://www.readbyqxmd.com/read/29790694/advances-in-antibody-therapeutics-targeting-small-cell-lung-cancer
#6
REVIEW
Hongyang Lu, Zhiming Jiang
The proportion of small-cell lung cancer (SCLC) among all lung cancers decreased from 17.26% in 1986 to 12.95% in 2002. Chemotherapy is the key mode of treatment. However, novel therapeutic strategies and drugs are imperative, as the prognosis remains poor. In recent years, antibody therapies have shown promising prospects against malignancy. This review focuses on the advances in antibody therapies in SCLC. Although the results of pembrolizumab, nivolumab, ipilimumab, and rovalpituzumab tesirine are inspiring, all of the clinical trials on these drugs are phase I/II and have been verified for further phase III clinical trials...
May 16, 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29789716/xct-slc7a11-mediated-metabolic-reprogramming-promotes-non-small-cell-lung-cancer-progression
#7
Xiangming Ji, Jun Qian, S M Jamshedur Rahman, Peter J Siska, Yong Zou, Bradford K Harris, Megan D Hoeksema, Irina A Trenary, Chen Heidi, Rosana Eisenberg, Jeffrey C Rathmell, Jamey D Young, Pierre P Massion
Many tumors increase uptake and dependence on glucose, cystine or glutamine. These basic observations on cancer cell metabolism have opened multiple new diagnostic and therapeutic avenues in cancer research. Recent studies demonstrated that smoking could induce the expression of xCT (SLC7A11) in oral cancer cells, suggesting that overexpression of xCT may support lung tumor progression. We hypothesized that overexpression of xCT occurs in lung cancer cells to satisfy the metabolic requirements for growth and survival...
May 23, 2018: Oncogene
https://www.readbyqxmd.com/read/29789636/cypripedin-diminishes-an-epithelial-to-mesenchymal-transition-in-non-small-cell-lung-cancer-cells-through-suppression-of-akt-gsk-3%C3%AE-signalling
#8
Surassawadee Treesuwan, Boonchoo Sritularak, Pithi Chanvorachote, Varisa Pongrakhananon
Lung cancer appears to have the highest rate of mortality among cancers due to its metastasis capability. To achieve metastasis, cancer cells acquire the ability to undergo a switch from epithelial to mesenchymal behaviour, termed the epithelial-to-mesenchymal transition (EMT), which is associated with poor clinical outcomes. Drug discovery attempts have been made to find potent compounds that will suppress EMT. Cypripedin, a phenanthrenequinone isolated from Thai orchid, Dendrobium densiflorum, exhibits diverse pharmacological activities...
May 22, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29789623/mir-29c-reduces-the-cisplatin-resistance-of-non-small-cell-lung-cancer-cells-by-negatively-regulating-the-pi3k-akt-pathway
#9
Dian-Min Sun, Bu-Fu Tang, Zhen-Xiang Li, Hong-Bo Guo, Jin-Ling Cheng, Ping-Ping Song, Xin Zhao
In previous studies, miR-29s showed tumor suppressor properties against lung cancer, which improved the survival of patients upon the administration of chemotherapy via an unknown mechanism. Here, we investigated the regulatory effects of miR-29s on the cisplatin resistance of NSCLC cells. The expression of miR-29s was assessed in 130 clinical patients and in cisplatin-treated NSCLS cell lines. MiR-29c expression was decreased in 77% of NSCLC patients. Cisplatin treatment increased the expression of miR-29c and decreased the expression of its oncogenic target AKT2 in NSCLC cell lines...
May 22, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29789542/rnf25-promotes-gefitinib-resistance-in-egfr-mutant-nsclc-cells-by-inducing-nf-%C3%AE%C2%BAb-mediated-erk-reactivation
#10
Jung Hee Cho, Yeon-Mi You, Young Il Yeom, Dong Chul Lee, Bo-Kyung Kim, Misun Won, Byoung Chul Cho, Minho Kang, Seulki Park, Suk-Jin Yang, Jang Seong Kim, Jung-Ae Kim, Kyung Chan Park
Non-small cell lung cancer (NSCLC) patients with EGFR mutations initially respond well to EGFR tyrosine kinase inhibitors (TKIs) but eventually exhibit acquired or innate resistance to the therapies typically due to gene mutations, such as EGFR T790M mutation or a second mutation in the downstream pathways of EGFR. Importantly, a significant portion of NSCLC patients shows TKI resistance without any known mechanisms, calling more comprehensive studies to reveal the underlying mechanisms. Here, we investigated a synthetic lethality with gefitinib using a genome-wide RNAi screen in TKI-resistant EGFR-mutant NSCLC cells, and identified RNF25 as a novel factor related to gefitinib resistance...
May 22, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29789220/adaura-phase-iii-double-blind-randomized-study-of-osimertinib-versus-placebo-in-egfr-mutation-positive-early-stage-nsclc-after-complete-surgical-resection
#11
Yi-Long Wu, Roy S Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti, Masahiro Tsuboi
INTRODUCTION: Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non-small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifier, NCT02511106) trial, a multicenter, double-blind, randomized, placebo-controlled study. PATIENTS AND METHODS: Study entry will be limited to adults aged ≥ 18 years (and in Japan and Taiwan, age ≥ 20 years) with primary nonsquamous stage IB-IIIA non-small-cell lung cancer with central confirmation of an EGFR exon 19 deletion or L858R mutation...
May 1, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29789021/epidermal-growth-factor-receptor-egfr-t790m-mutation-identified-in-plasma-indicates-failure-sites-and-predicts-clinical-prognosis-in-non-small-cell-lung-cancer-progression-during-first-generation-tyrosine-kinase-inhibitor-therapy-a-prospective-observational
#12
Shirong Zhang, Lucheng Zhu, Bing Xia, Enguo Chen, Qiong Zhao, Xiaochen Zhang, Xueqin Chen, Xufeng Chen, Shenglin Ma
INTRODUCTION: Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of resistance to first-generation EGFR-tyrosine kinase inhibitor (TKI) therapy. The present study aimed to explore the association of ctDNA-identified T790M mutation with disease failure sites and clinical prognosis in non-small cell lung cancer (NSCLC) patients. METHODS: Patients who progressed on first-generation TKIs were categorized into failure site groups of chest limited (CF), brain limited (BF) and other (OF)...
May 22, 2018: Cancer communications
https://www.readbyqxmd.com/read/29788107/n2-lung-cancer-is-not-all-the-same-an-analysis-of-different-prognostic-groups
#13
Pietro Bertoglio, Sara Ricciardi, Greta Alì, Vittorio Aprile, Stylianos Korasidis, Gerardo Palmiero, Gabriella Fontanini, Alfredo Mussi, Marco Lucchi
OBJECTIVES: The International Association for the Study of Lung Cancer (IASLC) recently proposed a change in the staging system for N2, based on the metastatic station number: N2a1 (a single metastatic station with no hilar involvement), N2a2 (a single metastatic station with hilar involvement) and N2b (multiple metastatic stations). The aim of our study was to validate the IASLC proposal in a cohort of patients with pathological N2 disease. METHODS: All patients with pathological T1-T2 N2 non-small-cell lung cancer who were operated on between 2006 and 2010 in our department were enrolled...
May 19, 2018: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29788086/prognostic-ability-of-new-t1-descriptors-in-the-tumour-node-and-metastasis-classification-of-surgically-treated-non-small-cell-lung-cancer
#14
Tomoyoshi Takenaka, Koji Yamazaki, Naoko Miura, Sadanori Takeo
OBJECTIVES: In the tumour, node and metastasis (TNM) classification (8th edition) of non-small-cell lung cancer, T (tumour size) is determined solely according to the size of the solid component determined using computed tomography (CT). However, it is unclear whether tumours of equal size but with differing solid and part-solid components should be similarly treated. Herein, we assessed the prognostic significance of the newly proposed T1 descriptors with respect to the size of the solid component...
May 19, 2018: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29787943/venous-thromboembolism-with-egfr-monoclonal-antibody-necitumumab-in-stage-iv-non-small-cell-lung-cancer-a-retrospective-cohort-analysis
#15
Kelvin Young, Luis Paz-Ares, Nick Thatcher, David R Spigel, Javad Shahidi, Victoria Soldatenkova, Gerrit Grau, Raffael Kurek, Frances A Shepherd
INTRODUCTION: Metastatic non-small cell lung cancer (NSCLC) is a recognized risk factor for VTE. Some systemic treatments may increase this risk further. Here, we present the risk of VTE and its prognostic significance for patients treated with chemotherapy (chemo) and the EGFR monoclonal antibody necitumumab (neci) for metastatic NSCLC. METHODS: Four trials of 1st-line treatment for Stage IV NSCLC were analyzed: two randomized phase 3 studies of cisplatin/gemcitabine ±neci in squamous NSCLC (SQUIRE: N = 1079) and cisplatin/pemetrexed ±neci in non-squamous NSCLC (INSPIRE: N = 616); JFCL (N = 161), a randomized phase 2 trial of carboplatin/paclitaxel ±neci in squamous NSCLC; and JFCK (N = 61), a single arm phase 2 trial of cisplatin/gemcitabine +neci in squamous NSCLC...
May 7, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29787863/validity-of-targeted-next-generation-sequencing-in-routine-care-for-identifying-clinically-relevant-molecular-profiles-in-non-small-cell-lung-cancer-results-of-a-2-year-experience-on-1-343-samples
#16
Antoine Legras, Marc Barritault, Anne Tallet, Elizabeth Fabre, Alice Guyard, Bastien Rance, William Digan, Nicolas Pecuchet, Etienne Giroux-Leprieur, Catherine Julie, Stéphane Jouveshomme, Véronique Duchatelle, Véronique Giraudet, Laure Gibault, Alain Cazier, Jean Pastre, Françoise LE Pimpec-Barthes, Pierre Laurent-Puig, Hélène Blons
Theranostic assays are based on single gene testing but the ability of next-generation sequencing (NGS) to interrogate numerous genetic alterations will progressively replace single gene assays. Although NGS was evaluated to screen for theranostic mutations, its usefulness in clinical practice on large series of samples remains to be demonstrated. NGS performance was assessed following guidelines. TaqMan probes and NGS were compared for their ability to detect EGFR and KRAS mutations and NGS mutation profiles were analyzed on a large series of NSCLC (n=1,343)...
May 19, 2018: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/29787820/clinicopathological-characteristics-of-thyroid-transcription-factor-1-negative-small-cell-lung-cancers
#17
Yuko Iida, Shinobu Masuda, Yoko Nakanishi, Tetsuo Shimizu, Haruna Nishimaki, Mai Takahashi, Mari Hikichi, Shuichiro Maruoka, Yasuhiro Gon, Noriaki Takahashi, Shu Hashimoto
Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer (NSCLC); however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (achaete-scute homolog like 1 (ASCL1), BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (Nuclear Factor 1B (NF1B))...
May 19, 2018: Human Pathology
https://www.readbyqxmd.com/read/29787750/erybraedin-a-is-a-potential-src-inhibitor-that-blocks-the-adhesion-and-viability-of-non-small-cell-lung-cancer-cells
#18
Hye-Young Min, Yujin Jung, Kwan Hee Park, Won Keun Oh, Ho-Young Lee
The adhesion of cancer cells to the extracellular matrix (ECM) is crucial for cell proliferation, survival, and metastasis. Thus, it is necessary to inhibit cell-ECM adhesion by blocking the activation of the associated signaling to control cancer. Here, we identify erybraedin A (EBA) as a potential Src inhibitor that blocks cell adhesion and viability in non-small-cell lung cancer (NSCLC). EBA significantly inhibited the adhesion of NSCLC cells to fibronectin. EBA also markedly inhibited the activation of Src and its downstream targets, including FAK and Akt...
May 19, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29787357/prophylactic-cranial-irradiation-versus-observation-in-radically-treated-stage-iii-non-small-cell-lung-cancer-a-randomized-phase-iii-nvalt-11-dlcrg-02-study
#19
Dirk De Ruysscher, Anne-Marie C Dingemans, John Praag, Jose Belderbos, Caroline Tissing-Tan, Judith Herder, Tjeerd Haitjema, Fred Ubbels, Frank Lagerwaard, Sherif Y El Sharouni, Jos A Stigt, Egbert Smit, Harm van Tinteren, Vincent van der Noort, Harry J M Groen
Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery...
May 22, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29786107/e3-ubiquitin-ligase-hakai-regulates-cell-growth-and-invasion-and-increases-the-chemosensitivity-to-cisplatin-in-non%C3%A2-small%C3%A2-cell-lung-cancer-cells
#20
Zi Liu, Yuqing Wu, Zijian Tao, Liang Ma
Hakai was originally identified as an E3 ubiquitin ligase of the E‑cadherin complex implicated in cell adhesion and invasion. Recently, emerging evidence has strongly suggested that Hakai serves a pivotal role in the tumorigenesis of certain tumors. However, the role of Hakai in non‑small‑cell lung cancer (NSCLC) and its underlying molecular mechanism have not been clarified. In the present study, it was observed that Hakai was highly expressed in NSCLC cell lines compared with human normal bronchial epithelial cells, and transfection with Hakai small interfering RNA significantly inhibited the growth of A549 and NCI‑H460 NSCLC cells...
May 17, 2018: International Journal of Molecular Medicine
keyword
keyword
8880
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"